Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.

@article{Gray2010ProtonPI,
  title={Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.},
  author={Shelly L. Gray and Andrea Z LaCroix and Joseph C. Larson and John Robbins and Jane A. Cauley and Joann E. Manson and Zhao Chen},
  journal={Archives of internal medicine},
  year={2010},
  volume={170 9},
  pages={765-71}
}
BACKGROUND Proton pump inhibitor (PPI) medications have been inconsistently shown to be associated with osteoporotic fractures. We examined the association of PPI use with bone outcomes (fracture, bone mineral density [BMD]). METHODS This prospective analysis included 161 806 postmenopausal women 50 to 79 years old, without history of hip fracture, enrolled in the Women's Health Initiative (WHI) Observational Study and Clinical Trials with a mean (SD) follow-up of 7.8 (1.6) years. Analyses… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 132 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Acid-Suppressive Medications and Risk of Bone Loss and Fracture in Older Adults

Calcified Tissue International • 2008
View 4 Excerpts
Highly Influenced

Use of proton pump inhibitors and risk of osteoporosis-related fractures.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne • 2008
View 3 Excerpts

DXA quality assurance . National Heart , Lung , and Blood Institute Web site

JE Ware, CD Sherbourne
Menopause • 2004

Similar Papers

Loading similar papers…